undamentalytics Newsletter
Sign in

Herbalife LTD. (HLF) stock

Add to watchlist

Add holding +

NYSE: HLF NYSE Personal Care Products Next results ~February 1, 2027

C+ Fundamentals grade

Herbalife LTD. is a US-listed company in the personal care products industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 59% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 59% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Herbalife LTD. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 2 selling4 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds127 adding, 114 cuttingOf 51 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Herbalife files

Where Herbalife LTD. stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $5.28bn, up 6.4% on a year earlier, faster than the 5.5% growth a quarter earlier. Free-cash-flow margin rose to 6.4% from 4.4% a year earlier. The diluted share count is up 3.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 5 financial-health checks.

Our model value for Herbalife is under review, so past values are not shown until it is resolved.

Source: 10-Q filed November 2, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~February 1, 2027 (estimated)

Herbalife LTD.'s trailing-twelve-month revenue grew 6.4% year on year, with a free-cash-flow margin of 6.4%. Where it stands out: gross margin of 77.6% ranks 1 of 21 personal care products companies we cover. Where it lags: change in share count of 3.3% ranks 19 of 19 personal care products companies we cover.

Our discounted-cash-flow model values the business at ~$50 per share in the base case (~$34–$71 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 55.3% while net income fell 44.0%: a 99pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Herbalife LTD.'s latest figures clears our strength thresholds.

Things to watch

  • Share dilution. Diluted shares rose 3.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 59% and a beta of 1.1 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 66.4% ranks 12 of 13 personal care products companies we cover (median 29.7%).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q3

Filed November 2, 2026
Earnings per share
$0.51 against an average estimate of $0.54: missed by 4.9%
Revenue
$1.35bn, up 6.0% on a year earlier
Next report
November 2, 2026; average EPS estimate $0.62

Herbalife's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.8%
  • 1 week0.0%
  • 1 month+5.7%
  • This year+3.0%
  • 1 year+66.0%
  • 5 years-69.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$5.3B
Operating margin
9.6%
Net margin
3.4%
EPS (TTM, diluted)
$1.69

Growth

Revenue growth
+6.4%
Change in growth rate
+0.8 pts
Share count change
+3.3%

Cash

Free cash flow (TTM)
$337M
FCF margin
6.4%
Stock pay % of revenue
0.8%

Earnings

Last results
November 2, 2026
Next results (est.)
February 1, 2027

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Herbalife LTD. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 59% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Herbalife LTD. as an operating company, with every model that fits that kind of business. Cost of equity 7.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.57 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$23 ~$21–$39 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Herbalife LTD. with Personal Care Products in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$26.81$24.07$33.86$58.95$47.67$48.05$40.93$14.88$15.26$6.69$12.89$13.28
Market value$4.6bn$4.1bn$5.6bn$8.8bn$6.8bn$6.5bn$4.4bn$1.5bn$1.5bn$680m$1.3bn$1.4bn
+ Net debt (− = net cash)$732m$604m$1.1bn$1.4bn$1.1bn$1.5bn$2.2bn$2.2bn$2.0bn$1.9bn$1.7bn$1.5bn
Enterprise value$5.3bn$4.7bn$6.7bn$10.2bn$7.8bn$8.0bn$6.7bn$3.7bn$3.5bn$2.6bn$3.0bn$3.0bn
Multiples
Price / sales 1.0x0.9x1.3x1.8x1.4x1.2x0.8x0.3x0.3x0.1x0.3x0.3x
Price / earnings 13.5x15.9x26.2x29.7x21.7x17.3x9.9x4.6x10.8x2.7x5.8x7.8x
Price / free cash flow 8.3x18.5x11.3x15.6x19.2x12.5x14.4x7.6x6.9x4.2x5.3x4.2x
EV / EBITDA 7.8x8.5x9.4x13.1x11.8x10.7x7.9x5.6x7.5x5.1x5.0x4.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

78 /100

Strong moat

How hard Herbalife's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 74.9% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 78.4%, moving by 1.5 percentage points (standard deviation) across 10 years.

  • Durability 11 / 20

    Operating margin has been a median 10.7%; its worst year was 6.7%.

  • Cash conversion 13 / 20

    Free cash flow was positive in 10 of 10 years, at a median 6.1% of revenue.

  • Discipline 19 / 20

    The diluted share count fell 6.4% over five years; stock-based pay has been a median 0.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (83 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.37 +12% $5.3bn +4%
Next $3.08 +30% $5.4bn +3%

Next year's EPS estimate has moved −2.4% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −10.4% on 90 days ago. In the last 30 days, 0 analysts raised Herbalife LTD.'s forecast and 2 cut it.

Consensus EPS forecast Herbalife LTD., last 90 days
$2.20 $2.40 $2.60 $2.80 $3.00 $3.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.64 Current fiscal year, 60 days ago: $2.64 Current fiscal year, 30 days ago: $2.56 Current fiscal year, 7 days ago: $2.37 Current fiscal year, Now: $2.37 $2.37 Next fiscal year, 90 days ago: $3.15 Next fiscal year, 60 days ago: $3.15 Next fiscal year, 30 days ago: $3.15 Next fiscal year, 7 days ago: $3.08 Next fiscal year, Now: $3.08 $3.08

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.64$3.15
60 days ago $2.64$3.15
30 days ago $2.56$3.15
7 days ago $2.37$3.08
Now $2.37$3.08

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.54 $0.51 −4.9%
Mar 2026 $0.61 $0.64 +5.4%
Dec 2025 $0.48 $0.45 −5.6%
Sept 2025 $0.46 $0.50 +8.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Nov 2026
Buy375%
Hold00%
Sell125%

Monthly trend

  1. Nov 20261214
  2. Oct 20261214

Counts of recommendations published by analysts covering Herbalife LTD., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.9%
of tradable shares
Days to cover
5.55
at average volume
Short interest, 1 month
−11%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
5.0%
of shares
Employees
8,500
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +66.0%

$8.00 on October 31, 2025 to $13.28

ThenNowEffect
Revenue (last 12 months) $4.9bn $5.2bn +5.5%
Net margin 6.6% 3.2% −52.1%
P/E multiple 2.5x 8.5x +238.4%
Share count 102m 105m −2.9%

Biggest factor: p/e multiple.

Last 3 years +0.2%

$13.26 on November 3, 2023 to $13.28

ThenNowEffect
Revenue (last 12 months) $5.0bn $5.2bn +3.1%
Net margin 4.5% 3.2% −29.5%
P/E multiple 5.8x 8.5x +46.2%
Share count 99m 105m −5.8%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
HLF−15%−64%+3%−56%+93%+3%
Industry peers (median)+32%−32%+6%−8%−34%−1%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
HLF58%33%50%50%67%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
HLF−36%−72%−46%−59%−30%−45%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 92% from February 4, 2019 to February 12, 2025. Getting back needed a 1103% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.98 – $19.96
From 52-week high
−33.5%
vs 50-day average
+4.4%
vs 200-day average
−5.1%
Volatility (1 year)
59%
Beta vs S&P 500
1.10

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 5 down
typical move ±13.4%
After a week
7 up, 4 down
typical move ±17.8%
After a month
6 up, 5 down
typical move ±20.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −10.1% −0.4% −8.7% −4.9%
May 6, 2026 −10.9% +1.1% −20.0% −29.7%
April 14, 2026 +8.8% +2.0% +6.1% −16.3%
February 18, 2026 +22.8% +0.2% +20.8% −6.6%
November 5, 2025 +15.3% −0.7% +16.9% +52.9%
August 6, 2025 −8.9% +0.7% +3.1% +4.2%
April 30, 2025 −6.2% +0.7% −4.0% +10.5%
February 19, 2025 +38.5% −0.2% +48.9% +38.0%
October 30, 2024 +8.5% −2.3% +21.6% +11.6%
July 31, 2024 −9.4% +0.2% −26.2% −31.6%
May 1, 2024 +8.4% +0.6% +19.2% +19.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Herbalife LTD. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Herbalife LTD.
$4.9B $5B $5.1B $5.2B $5.3B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $5.1B Revenue (TTM), FY24 Q1: $5.1B Revenue (TTM), FY24 Q2: $5B Revenue (TTM), FY24 Q3: $5B Revenue (TTM), FY24 Q4: $5B Revenue (TTM), FY25 Q1: $5B Revenue (TTM), FY25 Q2: $4.9B Revenue (TTM), FY25 Q3: $5B Revenue (TTM), FY25 Q4: $5B Revenue (TTM), FY26 Q1: $5.1B Revenue (TTM), FY26 Q2: $5.2B Revenue (TTM), FY26 Q3: $5.3B $5.3B

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $5.1B
FY24 Q1 $5.1B
FY24 Q2 $5B
FY24 Q3 $5B
FY24 Q4 $5B
FY25 Q1 $5B
FY25 Q2 $4.9B
FY25 Q3 $5B
FY25 Q4 $5B
FY26 Q1 $5.1B
FY26 Q2 $5.2B
FY26 Q3 $5.3B
Revenue growth, TTM YoY Herbalife LTD.
-5% 0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -2.7% Revenue growth, TTM YoY, FY24 Q1: -0.9% Revenue growth, TTM YoY, FY24 Q2: -0.0% Revenue growth, TTM YoY, FY24 Q3: -0.5% Revenue growth, TTM YoY, FY24 Q4: -1.4% Revenue growth, TTM YoY, FY25 Q1: -2.4% Revenue growth, TTM YoY, FY25 Q2: -2.2% Revenue growth, TTM YoY, FY25 Q3: -0.8% Revenue growth, TTM YoY, FY25 Q4: 0.9% Revenue growth, TTM YoY, FY26 Q1: 3.7% Revenue growth, TTM YoY, FY26 Q2: 5.5% Revenue growth, TTM YoY, FY26 Q3: 6.4% 6.4%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -2.7%
FY24 Q1 -0.9%
FY24 Q2 -0.0%
FY24 Q3 -0.5%
FY24 Q4 -1.4%
FY25 Q1 -2.4%
FY25 Q2 -2.2%
FY25 Q3 -0.8%
FY25 Q4 0.9%
FY26 Q1 3.7%
FY26 Q2 5.5%
FY26 Q3 6.4%
Operating margin (TTM) Herbalife LTD.
6% 7% 8% 9% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 7.0% Operating margin (TTM), FY24 Q1: 7.1% Operating margin (TTM), FY24 Q2: 6.2% Operating margin (TTM), FY24 Q3: 6.7% Operating margin (TTM), FY24 Q4: 7.7% Operating margin (TTM), FY25 Q1: 8.8% Operating margin (TTM), FY25 Q2: 9.9% Operating margin (TTM), FY25 Q3: 9.8% Operating margin (TTM), FY25 Q4: 9.5% Operating margin (TTM), FY26 Q1: 9.7% Operating margin (TTM), FY26 Q2: 9.5% Operating margin (TTM), FY26 Q3: 9.6% 9.6%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 7.0%
FY24 Q1 7.1%
FY24 Q2 6.2%
FY24 Q3 6.7%
FY24 Q4 7.7%
FY25 Q1 8.8%
FY25 Q2 9.9%
FY25 Q3 9.8%
FY25 Q4 9.5%
FY26 Q1 9.7%
FY26 Q2 9.5%
FY26 Q3 9.6%
FCF margin (TTM) Herbalife LTD.
2% 4% 6% 8% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 4.4% FCF margin (TTM), FY24 Q1: 3.7% FCF margin (TTM), FY24 Q2: 3.1% FCF margin (TTM), FY24 Q3: 3.6% FCF margin (TTM), FY24 Q4: 3.3% FCF margin (TTM), FY25 Q1: 3.3% FCF margin (TTM), FY25 Q2: 3.5% FCF margin (TTM), FY25 Q3: 4.4% FCF margin (TTM), FY25 Q4: 5.0% FCF margin (TTM), FY26 Q1: 7.3% FCF margin (TTM), FY26 Q2: 6.2% FCF margin (TTM), FY26 Q3: 6.4% 6.4%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 4.4%
FY24 Q1 3.7%
FY24 Q2 3.1%
FY24 Q3 3.6%
FY24 Q4 3.3%
FY25 Q1 3.3%
FY25 Q2 3.5%
FY25 Q3 4.4%
FY25 Q4 5.0%
FY26 Q1 7.3%
FY26 Q2 6.2%
FY26 Q3 6.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Herbalife took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $5B
  2. Cost of revenue $1.1B · 22.1%
  3. Gross profit $3.9B · 77.9%
  4. Selling, general and admin $1.7B · 33.0%
  5. Other operating costs $1.8B · 35.3%
  6. Operating income $481M · 9.5%
  7. Income tax $47.3M · 0.9%
  8. Interest and other $205M · 4.1%
  9. Net income $228M · 4.5%

Shares of revenue. Source: Herbalife's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 2,325 2,734 3,455 4,072 4,825 4,959 4,469 4,488 4,428 4,892 4,877 5,542 5,803 5,204 5,062 4,993 5,038 5,277
Gross profit 1,831 2,175 2,774 3,260 3,862 3,976 3,613 3,634 3,579 3,973 3,919 4,391 4,564 4,031 3,871 3,889 3,923 4,095
EBITDA 358 456 634 736 820 607 682 556 717 784 666 741 842 661 470 507 602 626
Operating income 296 388 562 661 735 514 584 458 617 683 568 641 734 545 356 386 481 505
Net income 203 293 415 464 528 309 339 260 214 297 311 373 447 321 142 254 228 180
Diluted EPS $0.81 $1.16 $1.66 $1.97 $2.46 $1.70 $1.99 $1.51 $1.29 $1.98 $2.20 $2.77 $4.13 $3.23 $1.42 $2.50 $2.20 $1.69
Growth (year on year)
Revenue −1.5% +17.6% +26.3% +17.9% +18.5% +2.8% −9.9% +0.4% −1.4% +10.5% −0.3% +13.6% +4.7% −10.3% −2.7% −1.4% +0.9% +6.4%
EBITDA −5.9% +27.2% +39.0% +16.0% +11.4% −26.0% +12.3% −18.4% +28.8% +9.3% −15.0% +11.3% +13.6% −21.5% −28.9% +8.0% +18.7% +2.8%
Operating income −10.9% +30.9% +45.1% +17.6% +11.2% −30.2% +13.7% −21.5% +34.7% +10.7% −16.8% +12.8% +14.6% −25.7% −34.6% +8.3% +24.6% +3.5%
Net income −8.1% +44.0% +41.7% +11.8% +13.7% −41.5% +9.8% −23.3% −17.7% +38.7% +4.9% +19.8% +20.0% −28.2% −55.7% +78.8% −10.2% −44.0%
Diluted EPS −4.2% +44.1% +43.1% +18.7% +24.6% −30.8% +16.8% −23.9% −14.6% +53.5% +11.1% +25.9% +49.1% −21.8% −56.0% +76.1% −12.0% −45.7%
Margins
Gross margin 78.8% 79.6% 80.3% 80.0% 80.0% 80.2% 80.8% 81.0% 80.8% 81.2% 80.4% 79.2% 78.6% 77.4% 76.5% 77.9% 77.9% 77.6%
EBITDA margin 15.4% 16.7% 18.4% 18.1% 17.0% 12.2% 15.3% 12.4% 16.2% 16.0% 13.7% 13.4% 14.5% 12.7% 9.3% 10.2% 12.0% 11.9%
Operating margin 12.7% 14.2% 16.3% 16.2% 15.2% 10.4% 13.1% 10.2% 13.9% 14.0% 11.6% 11.6% 12.7% 10.5% 7.0% 7.7% 9.5% 9.6%
Net margin 8.7% 10.7% 12.0% 11.4% 10.9% 6.2% 7.6% 5.8% 4.8% 6.1% 6.4% 6.7% 7.7% 6.2% 2.8% 5.1% 4.5% 3.4%
Free-cash-flow margin 9.7% 11.7% 12.2% 11.0% 13.0% 6.8% 12.3% 5.0% 11.2% 11.5% 7.2% 9.3% 5.3% 3.8% 4.4% 3.3% 5.0% 6.4%
Cash flow
Cash from operations 285 388 511 568 773 511 629 367 591 648 458 629 460 353 358 285 333 396
Capital spending 60 68 90 122 147 174 79 143 96 84 106 112 151 156 135 122 80 59
Free cash flow 225 320 420 446 626 338 550 224 495 564 351 517 309 196 223 163 253 337
Stock-based pay 21 23 24 28 30 46 45 40 42 36 39 51 54 44 48 50 44 40
Free cash flow after stock pay 204 297 396 418 596 292 505 184 453 529 313 466 255 152 175 113 209 297
Balance sheet
Cash 151 191 259 334 973 645 890 844 1,279 1,199 839 1,045 602 508 575 415 353 409
Total debt 250 178 204 488 931 1,792 1,622 1,448 2,385 2,623 1,930 2,537 2,846 2,717 2,581 2,333 2,050 1,952
Net debt (negative = net cash) 100 −12 −55 154 −42 1,146 732 604 1,106 1,424 1,091 1,492 2,244 2,209 2,006 1,917 1,697 1,543
Diluted shares 252m 253m 250m 236m 215m 182m 171m 172m 166m 150m 142m 135m 108m 100m 100m 102m 104m 106m
Returned to shareholders
Dividends 49 54 85 135 123 30 0 0 0 0 — — — — — — — —
Buybacks 75 160 322 557 307 1,292 17 13 844 750 17 924 1,011 147 11 8 8 10
Total returned 123 214 407 692 430 1,322 17 13 844 750 17 924 1,011 147 11 8 8 10

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · September 30, 2026
What it owns · $2.9bn
Short-term assets $1.2bnLonger-term assets $1.7bn
What it owes, and who funded it · $3.3bn
Short-term liabilities $1.0bnLonger-term liabilities $2.3bnShareholders' equity $-410m
  • Short-term assets cover short-term liabilities $1.2bn of assets due within a year against $1.0bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.2bn short-term assets against $2.3bn of longer-dated liabilities.
  • More cash than debt $409m of cash against $1.9bn of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $396m of operating cash flow against $1.9bn of debt.
  • Operating profit covers interest at least five times over Operating income of $505m against $174m of interest.

From Herbalife LTD.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$10.3M
Buybacks, last 3 fiscal years
$27.5M
Diluted share count
+3.3%
year over year
Total shareholder yield
0.7%
dividends 0.0% + buybacks 0.7% of market value
Sales & admin spending
35.6%
of revenue

Competitors: side by side with peers

Closest by revenue in personal care products
Last 12 months unless stated HLF COTY BRBR EPC EL KVUE Median
Revenue, last 12 months $5.3bn $5.8bn $2.4bn $2.2bn $15.3bn $15.5bn $913m
Revenue growth, last 12 months 6.4% −1.5% 5.9% 11.6% 5.8% 3.5% 3.5%
Revenue growth, 3-year average 1.6% 1.5% 14.4% −0.2% −0.5% −0.0% −0.1%
Revenue growth, latest quarter 6.0% 1.3% 4.2% 1.7% 6.7% 3.2% 2.7%
Gross margin 77.6% 62.9% 28.6% 39.5% 76.0% 58.3% 69.2%
Operating margin 9.6% −1.4% 13.3% 0.8% 6.7% 17.4% 6.7%
Operating margin, 3-year average 8.7% 3.9% 16.1% 5.7% 2.7% 15.0% 5.5%
Net margin 3.4% −10.4% 7.3% −4.2% 2.4% 10.9% 3.4%
Cash from operations / revenue 7.5% 9.3% 9.9% 5.4% 12.7% 17.6% 9.9%
Free-cash-flow margin 6.4% 6.0% 9.6% 2.3% 9.9% 15.1% 9.6%
Free-cash-flow margin, 3-year average 4.8% 5.6% 9.3% −10.2% 8.6% 11.7% 6.0%
Stock pay / revenue 0.8% 0.8% 1.0% 0.9% 1.9% 0.8% 1.0%
Change in share count 3.3% 0.7% −7.9% −3.6% 1.2% −0.2% −0.0%

Median of all 21 companies we cover in personal care products. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

21 personal care products companies
Measure Company Peer median Rank
Revenue growth Growth 6.4% 3.5% 7 of 21
Change in growth rate Growth +0.8pp +0.7pp 10 of 21
Gross margin Profitability 77.6% 69.2% 1 of 21
Operating margin Profitability 9.6% 6.7% 9 of 21
Net margin Profitability 3.4% 3.4% 10 of 21
Free-cash-flow margin Cash generation 6.4% 9.6% 12 of 21
Stock pay as % of revenue Cash generation 0.8% 1.0% 5 of 18
Long-term debt as % of assets Balance sheet 66.4% 29.7% 12 of 13
Change in share count Balance sheet 3.3% -0.0% 19 of 19

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Weight Management $2.7B 54.5% ▼ 0.8%
Targeted Nutrition $1.5B 30.0% ▲ 1.7%
Energy Sports and Fitness $617M 12.3% ▲ 7.8%
Outer Nutrition $85M 1.7% ▲ 1.7%
Literature Promotional and Other $79.1M 1.6% ▼ 6.8%
Geography
Region Revenue Share YoY
Primary Reporting $4.8B 94.5% ▲ 1.3%
Others $2B 42.6% ▲ 1.2%
United States $1B 21.1% ▼ 1.9%
India $890M 18.7% ▲ 5.3%
Mexico $558M 11.7% ▲ 3.5%
China $279M 5.9% ▼ 6.2%
VN $278M 5.5% ▼ 1.9%

From Herbalife LTD.'s 10-K filed February 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.4B
Institutions reporting
233
Shares held vs prior quarter
▲ 0.2%
Positions opened / closed
31 / 43

Top buyers and sellers, Q2 2026: 127 institutions bought and 114 sold ; the biggest buyer was Solel Partners LP (+988K shares) and the biggest seller FMR LLC (−2.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Baupost Group LLC $122M 9.3M 8.8% 0.0%
Blackrock, Inc. $110M 8.4M 8.0% ▲ 7.0%
Route One Investment Company, L.P. $110M 8.3M 7.9% ▲ 1.5%
Vanguard Portfolio Management LLC $81.4M 6.2M 5.9% ▲ 1.7%
Renaissance Technologies LLC $66.1M 5.0M 4.8% ▼ 8.6%
Vanguard Capital Management LLC $58M 4.4M 4.2% ▼ 0.1%
Geode Capital Management, LLC $45.6M 3.5M 3.3% ▲ 31.8%
Solel Partners LP $37.5M 2.8M 2.7% ▲ 53.1%
LSV Asset Management $34.5M 2.6M 2.5% ▼ 0.1%
State Street Corp $33.5M 2.5M 2.4% ▲ 5.1%
FMR LLC $33.2M 2.5M 2.4% ▼ 52.0%
Two Sigma Investments, LP $30.7M 2.3M 2.2% ▲ 4.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Herbalife LTD.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $181,510 4 trades by 2 insiders, last 12 months Insider sales History → $2.6M 4 trades by 2 insiders · 0% under pre-set plans
Net ▼ $2.4M net selling
Insider Date Trade Shares Price Value
L'Helias Sophie Director June 4, 2026 Buy 1,200 $11.31 $13,572
Hicks Troy Chief Operating Officer May 19, 2026 Sell 10,000 $12.32 $123,200
Hicks Troy Chief Operating Officer May 18, 2026 Sell 38,377 $12.93 $496,215
Lamberti Frank Chief Commercial Officer May 12, 2026 Sell 134,982 $13.50 $1.8M
Lamberti Frank Chief Commercial Officer May 11, 2026 Sell 7,937 $13.86 $110,007
L'Helias Sophie Director December 1, 2025 Buy 800 $12.70 $10,160
L'Helias Sophie Director November 26, 2025 Buy 400 $13.22 $5,288
Cloud Lynda Director November 18, 2025 Buy 17,000 $8.97 $152,490

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

No trades in Herbalife LTD. disclosed in the last 12 months; 2 earlier trades on record.

  • Lamar Smith(TX):Sale (full), $1,001 - $15,000, traded October 13, 2017, filed November 20, 2017
  • Lamar Smith(TX):Purchase, $1,001 - $15,000, traded July 25, 2016, filed August 11, 2016

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around February 1, 2027 estimated from the company's past filing pattern, not announced

  • November 2, 2026
  • August 5, 2026
  • May 6, 2026
  • April 14, 2026
  • February 18, 2026
  • November 5, 2025

Recent SEC filings

Data status

When each part of this page on Herbalife LTD. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Herbalife LTD. in brief

What does Herbalife LTD. do?
Herbalife LTD. is a US-listed company in the personal care products industry. Its financial year ends in December.
What is Herbalife LTD.'s stock ticker?
Herbalife LTD. trades under the ticker HLF on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Herbalife LTD.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Herbalife LTD. reported revenue of $5.3B, 6.4% higher than a year earlier, according to its SEC filings.
What is Herbalife LTD.'s free cash flow?
Herbalife LTD.'s free-cash-flow margin is 6.4% of revenue over the trailing twelve months, ranking 12 of the 21 personal care products companies we cover.
Who are Herbalife LTD.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Baupost Group LLC, Blackrock, Inc. and Route One Investment Company, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Herbalife LTD. buying back stock, and does it pay a dividend?
Herbalife LTD. spent $10.3M on share repurchases over the trailing twelve months, and its diluted share count still rose 3.3% over the year.
What is Herbalife LTD.'s market cap?
On November 2, 2026, Herbalife LTD.'s market capitalisation was about $1.4B, with a price-to-earnings ratio of 7.8 and net debt of $1.5B. Market figures come from third-party market data and may be delayed.
Who are Herbalife LTD.'s competitors?
In our Personal Care Products peer group, the companies closest to Herbalife LTD. are Coty Inc., Bellring Brands, Inc., Edgewell Personal Care Co, The Estée Lauder Companies and Kenvue. The side-by-side comparison below sets their revenue, margins and growth against Herbalife LTD.'s.
Are insiders buying or selling Herbalife LTD. stock?
Over the last 12 months, Herbalife LTD.'s directors and officers reported 4 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Herbalife LTD.'s next earnings date?
Around February 1, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Herbalife LTD. announces its own schedule.